Literature DB >> 21988350

Associations of fibroblast growth factor 21 gene 3' untranslated region single-nucleotide polymorphisms with metabolic syndrome, obesity, and diabetes in a Han Chinese population.

Mei Zhang1, Li Zeng, You-Juan Wang, Zhen-Mei An, Bin-Wu Ying.   

Abstract

Fibroblast growth factor 21 (FGF-21) is a novel regulator for metabolic syndrome (MetS), diabetes, and obesity. However, no study has been performed on the association of these diseases with FGF-21 gene polymorphism. The aim of the study was to investigate the association of 3' untranslated region (UTR) single-nucleotide polymorphisms (SNPs) in the FGF-21 gene with MetS, obesity, and diabetes in the Han Chinese population. A total of 291 subjects were recruited from the Han Chinese population in Sichuan province. The genotypes of FGF-21 were determined by polymerase chain reaction-restriction fragment length polymorphism. The genotypes were confirmed by sequencing. No polymorphisms were found in rs11665841 (1 of 291) and rs3745706 (2 of 291). We did not find an association between genotype frequencies of SNP rs11665896 and lipid concentration, glucose concentration, or blood pressure. The TG/GG genotype relative to the TT genotype had an age- and sex-adjusted odds ratio of 1.41 for MetS (p=0.149), 1.84 (p=0.016) for obesity (body mass index ≥25 kg/m(2)), and 1.19 (p=0.492) for diabetes. Genetic variation of the 3' UTR of the FGF-21 gene was associated with obesity, however, not with MetS or diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21988350     DOI: 10.1089/dna.2011.1302

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  7 in total

Review 1.  Needles in the genetic haystack of lipid disorders: single nucleotide polymorphisms in the microRNA regulome.

Authors:  Praveen Sethupathy
Journal:  J Lipid Res       Date:  2013-03-15       Impact factor: 5.922

2.  Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians.

Authors:  Thomas Bobbert; Franziska Schwarz; Antje Fischer-Rosinsky; Andreas F H Pfeiffer; Matthias Möhlig; Knut Mai; Joachim Spranger
Journal:  Diabetes Care       Date:  2012-08-28       Impact factor: 19.112

Review 3.  Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy.

Authors:  Nobuyuki Itoh; Hiroya Ohta; Morichika Konishi
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-29       Impact factor: 5.555

Review 4.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

5.  Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study.

Authors:  Jung Ran Choi; Jang Young Kim; Il Hwan Park; Ji Hye Huh; Ki Woo Kim; Seung Kuy Cha; Kyu Sang Park; Joon Hyung Sohn; Jong Taek Park; Sang Baek Koh
Journal:  Yonsei Med J       Date:  2018-03       Impact factor: 2.759

6.  Molecular characterization and mapping of Fgf21 gene in a foodfish species asian seabass.

Authors:  Le Wang; Jun Hong Xia; Xiao Jun Liu; Peng Liu; Zi Yi Wan; Gen Hua Yue
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

Review 7.  FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases.

Authors:  Nobuyuki Itoh
Journal:  Front Endocrinol (Lausanne)       Date:  2014-07-07       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.